MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/acn3.51235

Медицинская библиотека · Annals of clinical and translational neurology · 2020

Viltolarsen in Japanese Duchenne muscular dystrophy patients: A phase 1/2 study.

Komaki Hirofumi, Takeshima Yasuhiro, Matsumura Tsuyoshi, Ozasa Shiro, Funato Michinori, Takeshita Eri, Iwata Yasuyuki, Yajima Hiroyuki, Egawa Yoichi, Toramoto Takuya, Tajima Masaya, Takeda Shinichi

Клиническое исследование I фазыКлиническое исследование II фазыСтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

OBJECTIVE

The novel morpholino antisense oligonucleotide viltolarsen targets exon 53 of the dystrophin gene, and could be an effective treatment for patients with Duchenne muscular dystrophy (DMD). We investigated viltolarsen's ability to induce dystrophin expression and examined its safety in DMD patients.

METHODS

In this open-label, multicenter, parallel-group, phase 1/2, exploratory study, 16 ambulant and nonambulant males aged 5-12 years with DMD received viltolarsen 40 or 80 mg/kg/week via intravenous infusion for 24 weeks. Primary endpoints were dystrophin expression and exon 53 skipping levels.

RESULTS

In western blot analysis, mean changes in dystrophin expression (% normal) from baseline to Weeks 12 and 24 were - 1.21 (P = 0.5136) and 1.46 (P = 0.1636), respectively, in the 40 mg/kg group, and 0.76 (P = 0.2367) and 4.81 (P = 0.0536), respectively, in the 80 mg/kg group. The increase in mean dystrophin level at Weeks 12 and 24 was significant in the 80 mg/kg group (2.78%; P = 0.0364). Patients receiving 80 mg/kg showed a higher mean exon 53 skipping level (42.4%) than those receiving 40 mg/kg (21.8%). All adverse events were judged to be mild or moderate in intensity and none led to study discontinuation.

INTERPRETATION: Treatment with viltolarsen 40 or 80 mg/kg elicited an increasing trend in dystrophin expression and exon 53 skipping levels, and was safe and well tolerated. The decline in motor function appeared less marked in patients with higher dystrophin levels; this may warrant further investigation. This study supports the potential clinical benefit of viltolarsen.

Для цитирования: Komaki Hirofumi, Takeshima Yasuhiro, Matsumura Tsuyoshi, Ozasa Shiro, Funato Michinori, Takeshita Eri, Iwata Yasuyuki, Yajima Hiroyuki, Egawa Yoichi, Toramoto Takuya, Tajima Masaya, Takeda Shinichi. Viltolarsen in Japanese Duchenne muscular dystrophy patients: A phase 1/2 study.. Annals of clinical and translational neurology. 2020. DOI: 10.1002/acn3.51235.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.